Verona Pharma
VRNA
VRNA was delisted on the 6th of October, 2025.
1 hedge funds and large institutions have $359K invested in Verona Pharma in 2025 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 238 closing their positions.
93.21% less ownership
Funds ownership: 93.24% → 0.02% (-93%)
100% less funds holding
Funds holding: 243 → 1 (-242)
100% less funds holding in top 10
Funds holding in top 10: 45 → 0 (-45)
100% less capital invested
Capital invested by funds: $8.57B → $359K (-$8.57B)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 238
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Pentwater Capital Management
Naples,
Florida
|
-$566M |
| 2 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$457M |
| 3 |
HI
HBK Investments
Dallas,
Texas
|
-$455M |
| 4 |
BlackRock
New York
|
-$408M |
| 5 |
Fidelity International
Hamilton,
Bermuda
|
-$372M |
VRNA Hedge Fund Activity: Q4 2025 in Review
1 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in Verona Pharma (VRNA) for Q4 2025, worth a combined $359K — down 100% from $8.57B a quarter earlier.
Sellers outnumbered buyers: 238 funds closed out of VRNA and 0 opened new positions — a net loss of 238 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Pentwater Capital Management, exiting entirely with an estimated $566M sold.
- 1 institutional investor held Verona Pharma (VRNA) as of Q4 2025, down from 243 in Q3 2025.
- Funds reported $359K of Verona Pharma stock for Q4 2025, down 100% quarter-over-quarter.
- 0 funds opened new Verona Pharma positions in Q4 2025 and 238 closed out, a net change of -238 holders.
- The largest Verona Pharma seller in Q4 2025 was Pentwater Capital Management, an estimated $566M sold.
Based on aggregated 13F filings for Q4 2025.